News stories about Prothena (NASDAQ:PRTA) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Prothena earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.6758000698368 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

Several analysts have commented on PRTA shares. Zacks Investment Research upgraded shares of Prothena from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a report on Friday, August 11th. Evercore ISI started coverage on shares of Prothena in a report on Wednesday, August 16th. They issued an “outperform” rating and a $83.00 price objective for the company. ValuEngine upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank Of Canada started coverage on shares of Prothena in a report on Thursday, September 14th. They issued an “outperform” rating and a $87.00 price objective for the company. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $79.00 price objective on shares of Prothena in a report on Thursday, September 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $76.75.

Prothena (PRTA) opened at $41.99 on Wednesday. Prothena has a one year low of $41.88 and a one year high of $70.00.

Prothena (NASDAQ:PRTA) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.41) by $0.04. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter last year, the firm earned ($1.26) earnings per share. The business’s revenue for the quarter was down 33.6% on a year-over-year basis. equities research analysts forecast that Prothena will post -4.27 earnings per share for the current year.

In other Prothena news, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $64.17, for a total transaction of $224,595.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tara Nickerson sold 17,500 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $63.60, for a total transaction of $1,113,000.00. Following the transaction, the insider now directly owns 19,500 shares of the company’s stock, valued at approximately $1,240,200. The disclosure for this sale can be found here. Insiders have sold 29,424 shares of company stock valued at $1,922,787 in the last ninety days. Insiders own 3.10% of the company’s stock.

WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Prothena (PRTA) Share Price” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://theolympiareport.com/2017/12/06/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-prothena-prta-share-price.html.

About Prothena

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.